Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/8283
Title: | Costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections | Authors: | Karahasanoğlu, Fatma Banu Asan, A. Saçar, Suzan Turgut, Hüseyin |
Keywords: | Chronic hepatitis B Chronic hepatitis C Cost adefovir entecavir lamivudine peginterferon alpha2a peginterferon alpha2b ribavirin tenofovir adolescent adult aged antiviral therapy article cost of illness cross-sectional study drug cost drug substitution drug withdrawal echography female follow up hepatitis B hepatitis C hospital cost human human tissue liver biopsy liver cirrhosis major clinical study male osteoporosis questionnaire Turkey (republic) virus carrier |
Publisher: | Galenos Publishing House | Abstract: | Background: Few studies have addressed the indirect costs of chronic hepatitis B and C, and none has assessed the real costs of these conditions, including indirect costs caused by loss of work, in Turkey. Aims: This study therefore analysed the costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections to the community. Study design: Cross-sectional study. Methods: This study analysed patients with chronic hepatitis B and hepatitis C treated at Pamukkale University Hospital Infectious Diseases and Clinical Microbiology Clinic, Denizli, Turkey between June 2009 and June 2010. Costs of antiviral treatment and follow-up were calculated from patients' medical records, and indirect costs were analysed from questionnaires completed by patients. Results: Data were analysed for 284 patients with chronic viral hepatitis. Indirect, hospital, treatment and total expenses were significantly higher for patients with chronic hepatitis B than for inactive hepatitis B virus carriers and patients with chronic hepatitis C. Hospital and total expenses of patients with complications were significantly higher than for patients with chronic hepatitis C. Hospital and total expenses were significantly higher for patients with than for individuals without cirrhosis. Indirect, hospital, treatment and total costs of patients were significantly higher for patients receiving combination therapy than monotherapy. Conclusion: Reducing the costs to society of chronic hepatitis requires the development of protection and screening programs. © Trakya University Faculty of Medicine. | URI: | https://hdl.handle.net/11499/8283 https://doi.org/10.5152/balkanmedj.2013.7547 |
ISSN: | 2146-3123 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
10.5152 balkanmedj.2013.7547.pdf | 128.67 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
7
checked on Sep 30, 2024
WEB OF SCIENCETM
Citations
6
checked on Sep 30, 2024
Page view(s)
50
checked on Aug 24, 2024
Download(s)
18
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.